コーパス検索結果 (right1)
通し番号をクリックするとPubMedの該当ページを表示します
2 ipants from Ontario, Canada, experiencing recurrence of CDI were randomly assigned in a 1:1 ratio to 14 days of oral vanc
4 December 2007, enrolled 168 patients with high-risk PCa who were randomly assigned in a 1:1 ratio to conventional (80 Gy
9 ostate cancer that had progressed after docetaxel treatment were randomly assigned in a 1:1 ratio to receive bone-directe
10 who were motivated to quit and called the national quitline were randomly assigned in a 1:1 ratio to receive cytisine for
11 s, patients with ST-segment elevation myocardial infarction were randomly assigned in a 1:1 ratio to receive EES or BMS.
16 breast cancer receiving treatment with aromatase inhibitors were randomly assigned in a 1:1 ratio to receive either denos
17 In the phase 2 part of the study, patients were randomly assigned in a 1:1 ratio to receive either olara
19 previously received a regimen containing an NS5A inhibitor were randomly assigned in a 1:1 ratio to receive either the n
21 complicated lower-urinary-tract infection or pyelonephritis were randomly assigned in a 1:1 ratio to receive intravenous
22 rombosis (EINSTEIN-DVT) or pulmonary embolism (EINSTEIN-PE) were randomly assigned in a 1:1 ratio to receive rivaroxaban
23 In a second trial, patients with HCV genotype 3 were randomly assigned in a 1:1 ratio to receive sofosbuvir-v
24 In one trial, patients with HCV genotype 2 were randomly assigned in a 1:1 ratio to receive sofosbuvir-v
25 previously received a DAA regimen but not an NS5A inhibitor were randomly assigned in a 1:1 ratio to receive sofosbuvir-v
26 th an estimated GFR of 25 to 44 ml per minute per 1.73 m(2) were randomly assigned in a 1:1 ratio to receive tolvaptan or
30 domized trial, 2008 patients with stable or unstable angina were randomly assigned in a 2:1 ratio to receive an everolimu
32 Patients who were taking a stable dose of methotrexate were randomly assigned in a 2:1 ratio to receive either adali
33 y-group assignments in the parent trials, eligible patients were randomly assigned in a 2:1 ratio to receive either evolo
34 nts with hereditary angioedema with C1 inhibitor deficiency were randomly assigned in a 2:1 ratio to receive either lanad
35 nd non-gBRCA cohort) and the type of non-gBRCA mutation and were randomly assigned in a 2:1 ratio to receive niraparib (3
40 Patients with HCV genotype 1, 2, 4, or 6 were randomly assigned in a 5:1 ratio to receive the nucleoti
47 superficial femoral and popliteal peripheral artery disease were randomly assigned in a 2:1 ratio to treatment with DCB o
49 ive clinical trials units (four in the UK and one in Malta) were randomly assigned in a 1:1 ratio to two vaccination grou
50 0 to 1), stratified by histology (epithelioid or biphasic), were randomly assigned in a 1:1 ratio to up to six cycles of
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。